US › Healthcare

Sensei Biotherapeutics Inc (SNSE)

US · Healthcare · Biotechnology

$25.96-28.23%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-170.2M
Profit YoY
-2380.1%
EPS
$-131.45
EPS estimate
$-0.62

EPS came in at -131.45 against a street estimate of -0.62 — a miss of 21101.6%.

Key statistics

Market cap
$18.6M
Forward P/E
0.0
P/B
1.26
Book value
$-102.43
EPS (TTM)
$-142.72
52-week high
$36.93
52-week low
$7.20
50-day MA
$21.49
200-day MA
$16.71
Beta
-0.23

Analyst view

Analysts rate Sensei Biotherapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $51.67.

Shareholding

Insiders
28.29%
Institutions
153.02%

Largest institutional holders

FundStake
Vivo Capital, LLC2.80%
Cormorant Asset Management, LLC1.19%
StemPoint Capital LP1.03%
Millennium Management LLC0.57%
Franklin Resources Inc0.52%
Caligan Partners LP0.49%
Trails Edge Capital Partners, LP0.48%
Marshall Wace Asset Management Ltd0.26%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sensei Biotherapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.